Smith D.C.Smith M.R.Sweeney C.Elfiky A.A.Logothetis C.Corn P.G.Vogelzang N.J.Small E.J.Harzstark A.L.Gordon M.S.Vaishampayan U.N.Haas N.B.Spira A.I.Lara Jr. P.N.CHIA-CHI LINSrinivas S.Sella A.Sch?ffski P.Scheffold C.Weitzman A.L.Hussain M.2022-09-152022-09-1520130732-183Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84874787799&doi=10.1200%2fJCO.2012.45.0494&partnerID=40&md5=1fb1733a99da42a3252887e6459c7338https://scholars.lib.ntu.edu.tw/handle/123456789/620323[SDGs]SDG3Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trialjournal article10.1200/JCO.2012.45.0494231695172-s2.0-84874787799